{"id":296427,"date":"2026-05-07T00:00:00","date_gmt":"2026-05-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0014-2022-biopharma-alzheimers-disease-unmet-need-unmet-need-agitation-in-alzheimers-disease\/"},"modified":"2026-05-08T11:19:48","modified_gmt":"2026-05-08T11:19:48","slug":"unnecg0014-2026-biopharma-alzheimers-disease-unmet-need-unmet-need-agitation-in-alzheimers-disease-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0014-2026-biopharma-alzheimers-disease-unmet-need-unmet-need-agitation-in-alzheimers-disease-us-eu\/","title":{"rendered":"Alzheimer&#8217;s Disease &#8211; Unmet Need &#8211; Unmet Need &#8211; Agitation in Alzheimer&#8217;s Disease (US\/EU)"},"content":{"rendered":"<p>Agitation affects most Alzheimer\u2019s disease (<abbr title=\"Alzheimer's disease\">AD<\/abbr>) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement. Agitation is commonly treated with off-label atypical antipsychotics, in spite of the safety warnings they carry related to the elevated risk of death in elderly dementia patients. In 2023, Lundbeck \/ Otsuka\u2019s Rexulti (brexpiprazole) became the first <abbr title=\"Food and Drug Administration\">FDA<\/abbr>-approved drug to treat agitation associated with <abbr title=\"Alzheimer's disease\">AD<\/abbr>. Other novel agents are emerging as potential treatments (e.g., Axsome\u2019s AXS-05 [Auvelity], Bristol Myers Squibb\u2019s KarXT [Cobenfy]). Understanding the drivers of clinical decision-making in agitation and prescriber perceptions of the risk \/ benefit profiles of today\u2019s approved brand and off-label generic options will help to identify levers for new product positioning and differentiation in this evolving market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the most important clinical attributes influencing prescribing for agitation in <abbr title=\"Alzheimer's disease\">AD<\/abbr> (e.g., impact on agitation, risk of extrapyramidal symptoms, delivery profile, scope of nonfinancial patient \/ caregiver support)?<\/li>\n<li>How do Rexulti and off-label agents (i.e., quetiapine, risperidone, olanzapine, aripiprazole, citalopram, dextromethorphan \/ quinidine) perform on these attributes?<\/li>\n<li>Based on a conjoint analysis and TPP simulation, what trade-offs across key clinical attributes (e.g., impact on Cohen-Mansfield Agitation Inventory, incidence of dizziness and extrapyramidal symptoms, delivery profile) and price are neurologists willing to make for a hypothetical new drug to treat agitation in <abbr title=\"Alzheimer's disease\">AD<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW54210101 BCX8 round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 32 European neurologists fielded in February 2026<\/p>\n<p><strong>Key companies:<\/strong> Otsuka \/ Lundbeck<\/p>\n<p><strong>Key drugs:<\/strong> Rexulti, quetiapine, risperidone, olanzapine, aripiprazole, citalopram, dextromethorphan \/ quinidine<\/p>\n<div>\n<p><strong>Key feature <\/strong><\/p>\n<\/div>\n<div>\n<p>Target Product Profile (<abbr title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n<\/div>\n","protected":false},"template":"","class_list":["post-296427","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-therapy-areas-neurology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":4,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296427\/revisions"}],"predecessor-version":[{"id":581263,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296427\/revisions\/581263"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}